• Aucun résultat trouvé

Which incretin-based therapy for type 2 diabetes?

N/A
N/A
Protected

Academic year: 2021

Partager "Which incretin-based therapy for type 2 diabetes?"

Copied!
7
0
0

Texte intégral

Loading

Figure

Table 1 : Head-to-head trials of > 24 weeks duration comparing a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) with either twice-daily  exenatide or once-daily liraglutide in patients with type 2 diabetes not well controlled with oral

Références

Documents relatifs

Enseignements pour la pratique clinique - Confirmation de l’efficacité de l’alfuzosine sur le long terme dans le contexte d’une pathologie exposant à de nombreuses années

The major advantages of this study in which we developed a population pharmacokinetic model for both formulations in comparison to a model developed for

Type 2 Diabetes Mellitus (T2DM) leads to bone fragility and predisposes to increased risk of 19.. fracture, poor bone healing and other

The aim of the present meta-analysis was to assess whether patients with T2DM treated with GLP-1 receptor agonists (GLP-1Ra) present a lower incidence of

In add- ition, there is consistent evidence based on clinical data that adherence in once-daily (QD) regimen is superior to twice-daily (BID) appli- cation, in particular with regard

The aim of our study was therefore to investigate the relationship between remission status and meal- stimulated proinsulin, C-peptide, GLP-1, and glucagon plasma concentrations in

Type 2 Diabetes Mellitus (T2DM) leads to bone fragility and predisposes to increased risk of 19.. fracture, poor bone healing and other

The aim of the present meta-analysis was to assess whether patients with T2DM treated with GLP-1 receptor agonists (GLP-1Ra) present a lower incidence of